Summary Paragraph Clause Samples

Summary Paragraph. State, local, tribal, and territorial public health systems must continue to sustain emergency preparedness and response capability and demonstrate operational readiness to respond to public health threats and emergencies. This notice of funding opportunity (NOFO) supports strengthening the capability of public health systems to effectively prepare for and respond to public health threats and emergencies. This announcement provides expectations and priorities for funded recipients to enhance their readiness to save lives during emergency incidents that exceed the day-to-day capacity and capability of public health response agencies. It serves as a roadmap to ensure that PHEP recipients develop strategies and activities that will increase their ability to be operationally ready to execute plans, respond to, and recover from public health threats and emergencies. PHEP funding will ensure PHEP recipients continue to develop and sustain effective public health emergency management and response capability according to standards described in the Public Health Emergency Preparedness and Response Capabilities: National Standards for State, Local, Tribal, and Territorial Public Health. These standards provide a framework to ensure that PHEP recipients, based on the PHEP logic model, apply findings from their jurisdictional risk assessments, capability self-assessments, and after-action reports to inform their strategic priorities and direct jurisdictional preparedness investments. a. Eligible Applicants: Limited b. NOFO Type: Cooperative Agreement c. Approximate Number of Awards: 62 d. Total Period of Performance Funding: $3,061,250,000 e. Average One Year Award Amount: $10,000,000 f. Total Period of Performance Length: 5 g. Estimated Award Date: 07/01/2019 h. Cost Sharing and / or Matching Requirements: Y
View SourceView Similar (3)
Summary Paragraph. This CDC notice of funding opportunity (NOFO) seeks to enhance the nation’s ability to rapidly mobilize, surge, and respond to a public health emergency (PHE) identified by CDC. This NOFO is intended to establish a new roster of approved but unfunded (ABU) public health departments that may receive rapid funding by CDC to respond to a PHE of such magnitude, complexity, or significance that they would have an overwhelming impact upon, and exceed resources available to, the jurisdictions. CDC will use this ABU list for emergencies that require federal support to effectively respond to, manage, and address identified public health threats. Funding related to this NOFO will only be made available once CDC has determined a PHE exists or is considered eminent, and is contingent upon the availability of appropriations, and will be at CDC’s sole discretion. CDC will provide additional guidance and information to those on the ABU list when this NOFO is funded. This current application period is open to those jurisdictions that want to renew their status on CDC’s fiscal year 2019 ABU list and eligible entities that did not submit applications when this NOFO was first published in 2017. See Section H for more information on application requirements. a. Eligible Applicants: Limited b. NOFO Type: Cooperative Agreement c. Approximate Number of Awards: 69 d. Total Period of Performance Funding: $345,000,000 e. Average One Year Award Amount: $5,000,000 f. Total Period of Performance Length: 1.33 g. Estimated Award Date: 02/01/2019 h. Cost Sharing and / or Matching Requirements: N No cost sharing or matching is required.
View SourceView Similar (2)
Summary Paragraph. This CDC notice of funding opportunity (NOFO) seeks to enhance the nation’s ability to rapidly mobilize, surge, and respond to a public health emergency (PHE) identified by CDC. This NOFO is intended to establish a roster of approved but unfunded (ABU) applicants that may receive rapid funding by CDC to respond to a PHE of such magnitude, complexity, or significance that it would have an overwhelming impact upon, and exceed resources available to, the jurisdictions. CDC will use this ABU list for emergencies that require federal support to effectively respond to, manage, and address identified public health threats. CDC will make funding related to this NOFO available once it has determined a PHE exists or is considered imminent and is contingent upon the availability and stipulations of appropriations. CDC will provide additional guidance and information to those on the ABU list when this NOFO is funded. Applicants may be selected to receive initial funding for Component A to stand up emergency activities, surge staffing, activate their EOCs, and conduct a needs assessment to determine the resources needed to address the specific public health crisis. Component B will provide for tailored emergency response activities. Components A and B can be issued independently or simultaneously based upon the unique needs and nature of the specific emergency. Awards and funding are subject to availability of funds. a. Funding Instrument Type: b. Approximate Number of Awards c. Total Period of Performance Funding: d. Average One Year Award Amount:
View SourceView Similar (2)
Summary Paragraph. CDC announces a new cooperative agreement (CoAg) for eligible federally recognized tribal nations and regional AI/AN tribally designated organizations to strengthen and improve the public health infrastructure and performance of tribal public health systems. This program's intent is to assist tribal entities with strengthening tribal public health leadership and workforce; improving access to tribal-specific data, surveillance, and analytics; developing and adapting evidence-based or evidence-informed programs, services, and resources; and improving public health policies and organizational practices that increase the sustainability of the collective tribal public health system. Ultimately, this CoAg aims to 1) decrease morbidity and mortality among American Indians/Alaska Natives (AI/ANs); 2) advance the capacity of Indian Country to identify, respond to, and mitigate public health threats; 3) improve the capacity of the workforce to deliver essential public health services; 4) increased culturally-appropriate practice-based evidence programs and policies that are effective and sustainable throughout Indian Country; and 5) improve the capacity to collaboratively and strategically address AI/AN health needs and advance health equity. a. Eligible Applicants: Limited b. NOFO Type: Cooperative Agreement c. Approximate Number of Awards: 25 d. Total Period of Performance Funding: $62,500,000 e. Average One Year Award Amount: $50,000 f. Total Period of Performance Length: 5
View Source
Summary Paragraph. This FOA is for the continued purpose of strengthening and enhancing the capabilities of state, local, and territorial public health and health care systems to respond effectively (mitigate the loss of life and
View Source
Summary Paragraph. Through this Notice of Funding Opportunity (NOFO), CDC seeks to enhance the nation’s ability to rapidly mobilize, surge, and respond to public health emergencies identified by CDC. This NOFO is intended to establish a roster of public health departments that would be pre- identified and pre-approved for rapid funding by CDC for public health emergencies of such magnitude, complexity, or significance that it would have an overwhelming impact upon, and exceed resources available to, the jurisdiction. This NOFO will establish an Approved-But- Unfunded (ABU) list of grantees. This ABU list would be utilized by CDC for such emergencies that require federal support to effectively respond to, manage, and address the identified public health threat. As this NOFO’s purpose is to create a list of pre-approved health departments, any funding tied to this NOFO will only be made available once CDC has determined a public health emergency exists or is considered imminent. Thus, there is no funding available at the time of this announcement. Funding will be contingent upon the availability of appropriations and is at CDC’s sole discretion. CDC will provide additional guidance and information to those on the ABU list as to when this NOFO will be implemented. In addition, while this NOFO may be utilized in conjunction with or without a Secretarial declared emergency, a declaration may not trigger the activation of this NOFO.
View Source
Summary Paragraph. CDC announces available Fiscal Year (FY) 2020 funds to continue complementing TB prevention and control and laboratory services and activities at state and local levels to reduce TB morbidity and mortality. Goals include preventing transmission of M. tuberculosis (TB) and preventing persons from progressing from latent TB infection to TB disease. Funding levels will be determined by formulas reflecting TB disease incidence, case complexity, program performance, and laboratory workload data. Strategies and activities include diagnosis/treatment of persons with TB disease; persons with LTBI; evaluation of immigrants/refugees with TB or LTBI; targeted testing and treatment of LTBI; program planning, evaluation, and improvement; epidemiologic surveillance and response; human resource development and partnership activities; and public health laboratory strengthening. Expected outcomes include (not limited to): decreases in TB incidence; increases in patients completing treatment within 12 months; increases in TB cases with HIV and drug susceptibility testing results; increases in LTBI testing and treatment completion rates of those who are recommended for treatment; increases in accuracy and completeness of surveillance, genotyping, and whole-genome sequencing data; improvement in turnaround times for specimen receipt and laboratory testing; increases in programs implementing TB elimination plans; and increases in sharing of best practices within and between state/local programs. a. Eligible Applicants: Open Competition b. NOFO Type: Cooperative Agreement
View Source

Related to Summary Paragraph

  • FIRST PARAGRAPH The first paragraph to the ICE Trade Vault Agreement shall be amended by adding the following before the last sentence: “Participant is the Third Party Reporter for each of the entities listed in Exhibit 1 to this Annex L (as amended from time to time pursuant to Section 3(m) below), each of which is a “Client” of the Third Party Reporter.”

  • Sole Paragraph The Concessionaire will present to the competent agencies, whenever required, the reports of environmental impact, as well as will arrange for the achievement of the respective license, as per applicable legislation.

  • PREAMBLE The parties agree that this article constitutes the method and procedure for a final and conclusive settlement of any dispute (hereinafter referred to as "the grievance") respecting the interpretation, application, operation or alleged violation of this Collective Agreement, including a question as to whether a matter is arbitrable.

  • Agreement Preamble Alliance Manager 3.1 Anti-Corruption Laws 12.7(a)(i) Audited Party 9.10(b)(i) Auditing Party 9.10(b)(i) Breach Notification 15.2(b)(i) BTC Data Package 1.65 Claims 13.1 Clinical Supply Agreement 7.3(b) CMO 7.2 Commercial Supply Agreement 7.3(c) Commercialization Milestone Event 9.4 Commercialization Milestone Payment 9.4 Commitments Log 4.1 Confidentiality Agreement 17.11 Continuing Technology Transfer 4.1 Disclosing Party 1.21 Dispute 17.5(a) DMF 6.3 DOJ 16.2(a) Excluded Claim 1.1(e) Execution Date Preamble Executive Officers 17.5(a) Executive Sponsors 3.2(f) Existing Regulatory Materials 12.2(s) Ex-Territory Infringement 14.4(a) First BLA 6.2(b) FTC 16.2(b) Global Brand Elements 8.3(c) HSR Filing 16.1(a) ICH Guidelines 1.37 Indemnified Party 13.3 Indemnifying Party 13.3 Initial Technology Transfer 4.1 Jazz Preamble Jazz Collaboration IP 14.1(a) Jazz Collaboration Patent Rights 14.3(d) Jazz Competing Product 1.1(a) Jazz Indemnitee(s) 13.2 Jazz Publication 11.1(b) Joint Collaboration IP 14.1(a) Joint Patent Rights 14.1(d) JSC 3.2(a) License 2.1(b) Losses 13.1 Manufacturing Technology Transfer 7.2 Manufacturing Technology Transfer Plan 7.2 Manufacturing Transition Date 7.3(a) Manufacturing Working Group 3.2(g)(ii) Negotiation Period 2.8 Notice of Dispute 17.5(a) Offered Rights 2.8 Parties Preamble Party Preamble Patent Liaison 14.2 [*** ***] Post-Approval Commitments 6.7(b) PPQ 7.4(a) Product Infringement 14.4(a) Product Marks 14.9(a) Public Official 12.7(d) Publication 11.1(c) Quality Technical Agreement 7.3(d) Receiving Party 1.21 Regulatory Milestone Event 9.3 Regulatory Milestone Payment 9.3 Regulatory Working Group 3.2(g)(iii) Request Period 2.8 Review Period 11.1(b) Royalty Floor 9.6(c)(iii) Royalty Term 9.6(b) Safety Working Group 3.2(g)(iv) SDEA Agreement 6.4 SEC 11.3(c) Second Payment 9.1(b) Second Payment Due Date 9.1(b) Second Request 16.1(b) Securities Regulators 11.3(c) Technology Transfer 4.1 Term 15.1 Territory Development Plan 5.4 Upfront Payment 9.1(a) Western Europe 1.60 Working Group 3.2(g)(i) [*** ***] Zanidatamab 1.50 Zymeworks Preamble Zymeworks Collaboration IP 14.1(a) Zymeworks Competing Product 1.1(b) Zymeworks Development Plan 5.2(a) Zymeworks Domain Names 14.9(b)(v) Zymeworks Indemnitee(s) 13.1 Zymeworks Manufacturing IP 7.2 Zymeworks Platform Patents 1.79 Zymeworks Publication 11.1(c)

  • INTRODUCTORY STATEMENT Terms not defined in this Introductory Statement shall have the meanings specified in Article 1 hereof. Reference is made to that certain fixed rate loan in the original principal amount of $800,000,000 (the “Mortgage Loan”), evidenced by the following promissory notes: (a) that certain Promissory Note A-4, dated November 26, 2019 in the original principal amount of $400,000 made by the Borrower (as defined below) in favor of Citi Real Estate Funding Inc. (together with its successors in interest, “CREFI”) (such promissory note, as the same may hereafter be amended, restated, replaced, extended, renewed, supplemented, consolidated, severed, split or otherwise modified, “Note A-4”), (b) that certain Promissory Note A-5, dated November 26, 2019 in the original principal amount of $200,000 made by the Borrower in favor of G▇▇▇▇▇▇ S▇▇▇▇ Bank USA (together with its successors in interest, “GS Bank”) (such promissory note, as the same may hereafter be amended, restated, replaced, extended, renewed, supplemented, consolidated, severed, split or otherwise modified, “Note A-5”), (c) that certain Promissory Note A-6, dated November 26, 2019 in the original principal amount of $200,000 made by the Borrower in favor of Barclays Capital Real Estate Inc. (together with its successors in interest, “BCREI”) (such promissory note, as the same may hereafter be amended, restated, replaced, extended, renewed, supplemented, consolidated, severed, split or otherwise modified, “Note A-6”); (d) that certain Promissory Note A-7, dated November 26, 2019 in the original principal amount of $200,000 made by the Borrower in favor of BMO H▇▇▇▇▇ Bank N.A. (together with its successors in interest, “BMO H▇▇▇▇▇”) (such promissory note, as the same may hereafter be amended, restated, replaced, extended, renewed, supplemented, consolidated, severed, split or otherwise modified, “Note A-7”); (e) that certain Promissory Note B-1, dated November 26, 2019 in the original principal amount of $85,280,000 made by the Borrower (as defined below) in favor of CREFI) (such promissory note, as the same may hereafter be amended, restated, replaced, extended, renewed, supplemented, consolidated, severed, split or otherwise modified, “Note B-1”); (f) that certain Promissory Note B-2, dated November 26, 2019 in the original principal amount of $42,640,000 made by the Borrower in favor of GS Bank) (such promissory note, as the same may hereafter be amended, restated, replaced, extended, renewed, supplemented, consolidated, severed, split or otherwise modified, “Note B-2”); (g) that certain Promissory Note B-3, dated November 26, 2019 in the original principal amount of $42,640,000 made by the Borrower in favor of BCREI (such promissory note, as the same may hereafter be amended, restated, replaced, extended, renewed, supplemented, consolidated, severed, split or otherwise modified, “Note B-3”); (h) that certain Promissory Note B-4, dated November 26, 2019 in the original principal amount of $42,640,000 made by the Borrower in favor of BMO H▇▇▇▇▇ such promissory note, as the same may hereafter be amended, restated, replaced, extended, renewed, supplemented, consolidated, severed, split or otherwise modified, “Note B-4”); (i) that certain Promissory Note A-1-1, dated November 26, 2019 in the original principal amount of $50,000,000 made by the Borrower (as defined below) in favor of CREFI) (such promissory note, as the same may hereafter be amended, restated, replaced, extended, renewed, supplemented, consolidated, severed, split or otherwise